Jane Street
ORIC icon

Jane Street’s Oric Pharmaceuticals ORIC Stock Holding History

Jane Street’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$954K Buy
+75,300
New +$855K ﹤0.01% 6609

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Jane Street's ORIC Position: Q1 2026 in Review

Jane Street reduced its Oric Pharmaceuticals (ORIC) stake by 78% in Q1 2026, selling an estimated $2.17M and leaving 53,037 shares worth $672K. The position accounts for ﹤0.01% of the portfolio, ranked #7352.

Jane Street first reported a position in ORIC in Q2 2020 and has held it in 12 quarters since. The position peaked at $2M in Q4 2025. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

  • Jane Street held 53,037 shares of Oric Pharmaceuticals worth $672K as of Q1 2026.
  • Jane Street sold 190,996 Oric Pharmaceuticals shares in Q1 2026, an estimated $2.17M.
  • Oric Pharmaceuticals made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #7352 holding.
  • Jane Street first reported a position in Oric Pharmaceuticals in Q2 2020 and has held it in 12 quarters since.
  • Jane Street's Oric Pharmaceuticals position peaked at $2M in Q4 2025.
  • 182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.